Saturday, July 11, 2026

Drug profile · INN

escalation

escalation is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 4
Pipeline programs 43
News articles 0
Drug details — escalation
Class
Route
Patents
4
Programs
43
Data quality
0.70

Quick answer

escalation is an FDA-listed pharmaceutical active ingredient.

Key facts

INN escalation

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. De-escalation to ticagrelor 60 mg at day 30 Phase 3 · COLLEGIUM PHARMACEUTICAL · Non ST Segment Elevation Acute Coronary Syndrome
  2. 223050 Phase 2 · GSK Glaxo Smith · Neoplasms, Prostate
  3. ARI-HER2 Phase 2 · George Institute for · Patients with HER2Positive Advanced Breast Cancer
  4. BB-301: Dose escalation phase 1b cohort 1 Phase 2 · Benitec Biopharma · Oculopharyngeal Muscular Dystrophy
  5. CLIN-01194-450 Phase 2 · Ipsen · Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Sq
  6. CM-24 and Nivolumab - Dose Escalation Phase 2 · PURPLE BIOTECH · Solid Tumor
  7. CRN09682-191 Phase 2 · Anaxis Pharma · Metastatic or locally advanced SST2-positive neuroendocrine
  8. Dose Escalation Doublet: Combination of NKTR-214 + nivolumab Phase 2 · Nektar Therapeutics UK · Melanoma

Related patents

  1. US 10335460

    IL-15 and IL-15Rα heterodimer dose escalation regimens for treating conditions

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 8865230

    Compositions and methods for treating parasitic infections

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 8129510

    Minigene expression cassette

    Expires Mon Mar 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 7148193

    Compounds that bind to growth hormone receptor

    Expires Mon Dec 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is escalation?

escalation is an FDA-listed pharmaceutical active ingredient.